Patent classifications
A61P39/06
Ergothioneine compositions and methods for maintaining and/or increasing vitamin C levels in cells and organisms
Provided herein are methods and compositions for maintaining and/or increasing vitamin C in a cell or organism. The methods and compositions are based, in part, on the synergistic effect of ergothioneine, or a derivative thereof, on vitamin C levels in cells or organisms.
Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity
Compositions and methods for extending life expectancy are described herein. Specifically, ambroxol, ambroxol hydrochloride, and/or bromhexine can be used in a method for (a) treating, inhibiting, or reducing aging of a subject, (b) treating, inhibiting, or reducing an age-related symptom or an age-related disease in a subject, and/or (c) increasing the healthspan, lifespan, and/or mental acuity of a subject.
Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof
Disclosed in the invention are a type of compounds having aldolase selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for inhibiting triglyceride and cholesterol synthesis, for reducing fatty acid synthesis, for preventing and/or treating obesity and type II diabetes, for preventing and/or treating tumor, for preventing and/or treating Parkinson's disease, for preventing and/or treating Alzheimer's disease or for prolonging the lifespan of mammals: ##STR00001##
Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease
The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.
CLEOME DROSERIFOLIA EXTRACT AND THERAPEUTIC OR COSMETIC USE THEREOF
The invention relates to a Cleome droserifolia extract for topical application to the skin and/or mucous membranes. The invention also relates to the use of such an extract as well as to a process for obtaining it and to the compositions containing same.
CLEOME DROSERIFOLIA EXTRACT AND THERAPEUTIC OR COSMETIC USE THEREOF
The invention relates to a Cleome droserifolia extract for topical application to the skin and/or mucous membranes. The invention also relates to the use of such an extract as well as to a process for obtaining it and to the compositions containing same.
PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMPOSITION FOR ANIMAL, AND FOOD COMPOSITION, EACH COMPRISING NATURAL SUBSTANCE EXTRACT, AND PREPARATION METHOD THEREFOR
The present invention relates to a pharmaceutical composition, a pharmaceutical composition for animals, and a food composition, each composition comprising a Scutellaria baicalensis extract, a Liriope platyphylla extract, a Sophora flavescens extract, a Dictamnus root bark extract, and a Phellodendron amurense Ruprecht extract, and preparation methods therefor.
THE USE OF UNRIPENED GREEN MANGIFERA INDICA AS A NATURAL PREPARATION TO TREAT SARS-COV-2
The present disclosure provides a method for an effective decoction preparation of unripe green Mangifera indica to treat and prevent anti-SARS-CoV-2. The disclosure extends to uses of such preparation as medicaments and to methods of treating anti-SARS-CoV-2 infections, and tolerating the vaccine side-effects. The disclosure further extends to methods for preventing anti-SARS-CoV-2 infections by coating objects and surfaces with the compositions.
THE USE OF UNRIPENED GREEN MANGIFERA INDICA AS A NATURAL PREPARATION TO TREAT SARS-COV-2
The present disclosure provides a method for an effective decoction preparation of unripe green Mangifera indica to treat and prevent anti-SARS-CoV-2. The disclosure extends to uses of such preparation as medicaments and to methods of treating anti-SARS-CoV-2 infections, and tolerating the vaccine side-effects. The disclosure further extends to methods for preventing anti-SARS-CoV-2 infections by coating objects and surfaces with the compositions.
CERIUM OXIDE NANOPARTICLE, DISPERSION BODY, OXIDANT, ANTIOXIDANT, AND METHOD OF PRODUCING CERIUM OXIDE NANOPARTICLE
A cerium oxide nanoparticle is produced by mixing a solution of an aromatic heterocyclic compound having no substituent or at least one substituent selected from the group consisting of a methyl group, an ethyl group, an amino group, an aminomethyl group, a monomethylamino group, a dimethylamino group, and a cyano group and containing 2 to 8 carbon atoms and 1 to 4 nitrogen atoms in a ring structure of the aromatic heterocyclic compound, with a solution containing a cerium (III) ion or with a cerium (III) salt, followed by addition of an oxidant.